• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Lantern Pharma Inc. - Common Stock (NQ:LTRN)

    2.760 +0.270 (+10.84%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Apr 20, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Lantern Pharma Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 Next >
    BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) Schedules FDA Type C Meeting For HARMONIC Trial Amendments
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    Emerging Data for Lantern Pharma’s Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure — With No Added Toxicity
    From Lantern Pharma Inc.
    Via Business Wire
    News headline image
    RedChip's Biotech Investor Conference Replays Now Available
    Via ACCESS Newswire
    AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Launches withZeta.ai Platform, Opens New Revenue Stream
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    Lantern Pharma Launches withZeta.ai — the World’s First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development — Subscriptions Now Open; Debut Events at Nasdaq MarketSite on 4/16 and at AACR 2026 from 4/17 to 4/22
    From Lantern Pharma Inc.
    Via Business Wire
    AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) to Host April 9 Investor Briefing Featuring Live Demo Of withZeta.ai Platform
    Via Investor Brand Network
    Topics Artificial Intelligence
    MissionIRNewsBreaks – Lantern Pharma (NASDAQ: LTRN) to Host April 9 Investor Briefing Featuring Live Demo Of withZeta.ai Platform
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    RedChip Showcases Public Companies Driving Biotech Innovation at April 16 Virtual Investor Conference
    Via ACCESS Newswire
    News headline image
    Lantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Live Demo of withZeta.ai — the World's First Multi-Agentic Co-Scientist for Rare Cancers — 8:30 AM Eastern, April 9, 2026
    From Lantern Pharma Inc.
    Via Business Wire
    BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Advances AI-Driven Oncology Pipeline With Multiple 2026 Milestones in View
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
    From Lantern Pharma Inc.
    Via Business Wire
    News headline image
    New to The Street Broadcasts Show #740 on Bloomberg Television at 6:30 PM EST Featuring Medicus (MDCX), Acme Markets- Canton Foundation, Alpha Ton Capital (ATON), and Virtuix Holdings (NASDAQ:VTIX)
    Via ACCESS Newswire
    News headline image
    Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report
    From Lantern Pharma Inc.
    Via Business Wire
    InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Receives FDA Clearance For STAR-001 Pediatric CNS Cancer Trial
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001
    From Lantern Pharma Inc.
    Via Business Wire
    News headline image
    RedChip AI Investor Conference Replays Now Available Highlighting Companies Driving Innovation Across the AI Ecosystem
    Via ACCESS Newswire
    AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Schedules Fourth Quarter And Fiscal Year 2025 Results Webcast
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ET
    From Lantern Pharma Inc.
    Via Business Wire
    News headline image
    New to The Street Announces Broadcast of Show #739 on Bloomberg Television Across the U.S. at 6:30 PM EST
    Via ACCESS Newswire
    News headline image
    RedChip Highlights Public Companies Advancing the Next Phase of AI Adoption at Virtual Investor Conference on March 19
    Via ACCESS Newswire
    BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) to Present AI-Driven Neuro-Oncology Strategy at Glioblastoma Summit
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    Lantern Pharma to Present at the 7th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026
    From Lantern Pharma Inc.
    Via Business Wire
    BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) Receives FDA Orphan Drug Designation For LP-284 In Soft Tissue Sarcomas
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas
    From Lantern Pharma Inc.
    Via Business Wire
    AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Establishes AI Center of Excellence and Advanced Agentic Labs in India
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    Lantern Pharma Announces Establishing an A.I. Center of Excellence in India to Industrialize the RADR® Platform and Accelerate Global Development Opportunities with BioPharma Companies
    From Lantern Pharma Inc.
    Via Business Wire
    News headline image
    New to The Street Show #710 Airs Tonight at 6:30 PM EST on Bloomberg Television
    Via ACCESS Newswire
    BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Details Encouraging LP-184 Phase 1a Results Showing Durable Disease Control in Advanced Solid Tumors
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 Trials
    From Lantern Pharma Inc.
    Via Business Wire
    InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Q3 2025 Results and Highlights AI-Driven Clinical Progress
    Via Investor Brand Network
    Topics Artificial Intelligence
    < Previous 1 2 3 4 5 6 7 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.